Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

V Subbiah

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2021
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical researchC Belli, F Penault-Llorca, M Ladanyi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2022
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyV Subbiah, R J Kreitman, Z A Wainberg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2025
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumorsS P Chawla, E Abella, S Wieland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationS Fu, M M Hou, A Naing, et al.
ESMO Open|July 9, 2021
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphomaV Subbiah, S Kuravi, S Ganguly, et al.
ESMO Open|December 25, 2021
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkersM Palmeri, J Mehnert, A W Silk, et al.
ESMO Open|October 25, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I studyS Phadnis, X Wang, N C Daw, et al.
BMC Cancer|October 18, 2015
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseX Liu, G C George, A M Tsimberidou, et al.
JCO Precision Oncology|September 14, 2019
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsE Ileana Dumbrava, L Brusco, M Daniels, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
ESMO Open|August 29, 2022
Lurbinectedin, a selective inhibitor of oncogenic transcription, in patients with pretreated germline BRCA1/2 metastatic breast cancer: results from a phase II basket studyV Boni, B Pistilli, I Braña, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 18, 2021
ESMO recommendations on the standard methods to detect RET fusions and mutations in daily practice and clinical researchC Belli, F Penault-Llorca, M Ladanyi, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|January 13, 2022
Dabrafenib plus trametinib in patients with BRAF V600E-mutant anaplastic thyroid cancer: updated analysis from the phase II ROAR basket studyV Subbiah, R J Kreitman, Z A Wainberg, et al.
Medrxiv : the Preprint Server for Health Sciences|June 12, 2025
A first-in-human, Phase 1/2a, open-label study of SQ3370, a first-in-class doxorubicin-based click chemistry therapeutic, in patients with advanced solid tumorsS P Chawla, E Abella, S Wieland, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 12, 2015
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradationS Fu, M M Hou, A Naing, et al.
ESMO Open|July 9, 2021
Precision therapy with anaplastic lymphoma kinase inhibitor ceritinib in ALK-rearranged anaplastic large cell lymphomaV Subbiah, S Kuravi, S Ganguly, et al.
ESMO Open|December 25, 2021
Real-world application of tumor mutational burden-high (TMB-high) and microsatellite instability (MSI) confirms their utility as immunotherapy biomarkersM Palmeri, J Mehnert, A W Silk, et al.
ESMO Open|October 25, 2023
Everolimus in combination with vandetanib in children, adolescents, and young adults: a phase I studyS Phadnis, X Wang, N C Daw, et al.
BMC Cancer|October 18, 2015
Retreatment with anti-EGFR based therapies in metastatic colorectal cancer: impact of intervening time interval and prior anti-EGFR responseX Liu, G C George, A M Tsimberidou, et al.
JCO Precision Oncology|September 14, 2019
Expanded analysis of secondary germline findings from matched tumor/normal sequencing identifies additional clinically significant mutationsE Ileana Dumbrava, L Brusco, M Daniels, et al.
Pageof 6